Sanofi (SNY)

49.91
0.60 1.19
NASDAQ : Health Technology
Prev Close 50.51
Open 49.89
Day Low/High 49.76 / 50.06
52 Wk Low/High 37.62 / 55.00
Volume 4.49M
Avg Volume 1.74M
Exchange NASDAQ
Shares Outstanding 2.51B
Market Cap 129.93B
EPS 1.30
P/E Ratio 27.16
Div & Yield 1.17 (2.28%)
7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.

My Takeaways and Observations

The Chart of the Day demonstrates the widening schism between the real economy and stock prices.  The issuance of negative-yielding European corporate debt by Henkel, Deutsche Bahn and Sanofi are the definition of insanity. Euro bond prices are in t...

Tell Me Something I Don't Know

Regular readers of my diary know that I sometimes post something that replicates the theme of the Tell Me Something I Don't Know segment on MSNBC's Hardball With Chris Matthews. So ... "Tell me something I don't know, Dougie." OK, here goes: Henkel ...

Mylan Still Isn't Cheap

Mylan Still Isn't Cheap

The EpiPen controversy makes this stock a shot in the dark.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Clinton goes after the drug companies again -- for starters.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Bret Jensen Reporting for Duty

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg

Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg

The mobile-gaming market is expected to surpass console games this year, according to Deloitte.

Sanofi's Chart Shows Promise

Sanofi's Chart Shows Promise

Our first upside target is the $50 to $52 area and a close below $40 would extend the base.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Morning Movers: BCS, LYG, RBS, GOLD, AU, SNY

U.K. banks continue to get crushed in the wake of last week's Brexit vote as gold, a typical safe-haven investment, surged ahead.

BioMarin Pharmaceuticals Jumps on Takeover Talk

BioMarin Pharmaceuticals Jumps on Takeover Talk

Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

The uptick in the small- and mid-cap space bodes well for future capital appreciation.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

Cramer: Worst May Be Over for Embattled Pharma

The M&A activity is an incredible and a welcome sign.

M&A Could Ignite Next Leg Up for Biotech

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

A Good Morning So Far

The market is off to a good start, as the futures had portended earlier. Industrial and construction stocks seem to be doing particularly well. Rail-car maker Greenbrier Cos. (GBX) continues to show strength even after a recent earnings report that ...

Novice Trade: GlaxoSmithKline

Novice Trade: GlaxoSmithKline

Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.

MannKind Investors Should Have Seen the Writing on the Wall

MannKind Investors Should Have Seen the Writing on the Wall

Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.

2016 Could Be the Year of the Eurozone Stock Markets

The ECB's monetary stimulus is working, and more may be on the way.